Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
HUTCHMED (China) ( (HK:0013) ) has issued an update.
HUTCHMED (China) Limited has announced a Research & Development update event scheduled for October 31, 2025, in Shanghai and via webcast. The event will feature insights from Dr. Michael Shi on the company’s R&D strategy, focusing on its Antibody Targeted Therapy Conjugates platform and lead candidate HMPL-A251, as well as updates on late-stage pipeline development. This event highlights HUTCHMED’s ongoing commitment to advancing its therapeutic offerings and maintaining its position in the biopharmaceutical industry.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully brought drug candidates from in-house discovery to global markets, with its first three medicines marketed in China and one approved in the US, Europe, and Japan.
Average Trading Volume: 10,920,319
Technical Sentiment Signal: Hold
Current Market Cap: HK$21.87B
See more data about 0013 stock on TipRanks’ Stock Analysis page.